tbuckley/cabot-search huggingface dataset:
GEORGE CHEYNE (1671-1743) MASTER OF STYLE
Journal: JAMA (1968)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Biologic markers in risk assessment for environmental carcinogens
Authors: F. Perera, J. Mayer, R. M. Santella, D. Brenner, A. Jeffrey, L. Latriano, S. Smith, D. Warburton, T. L. Young, W. Y. Tsai, K. Hemminki, P. Brandt-Rauf
Journal: Environmental Health Perspectives (1991)

The potential of biologic markers to provide more timely and precise risk assessments for environmental carcinogens is viewed against the current state-of-the-art in biological monitoring/molecular epidemiology. Biologic markers such as carcinogen-DNA adducts and oncogene activation are currently considered valid qualitative indicators of potential risk, but for most chemical exposures research is needed to establish their validity as quantitative predictors of cancer risk. Biologic markers have, however, already provided valuable insights into the magnitude of interindividual variation in response to carcinogenic exposures, with major implications for risk assessment.
BBS volume 7 issue 2 Cover and Back matter
Authors: David Caplan, Andre Lecours, Allan Smith, Robert Berwick, Amy Weinberg, Ruth Garrett, Millikan Foreword, Daniel Dennett
Journal: Behavioral and Brain Sciences (1984)

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
HIV
Journal: JAMA (2002)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Toxicological Approaches to Complex Mixtures
Authors: Joe L. Mauderly
Journal: Environmental Health Perspectives (1993)

This paper reviews the role of toxicological studies in understanding the health effects of environmental exposures to mixtures.The approach taken is to review mixtures that have received the greatest emphasis from toxicology; major mixtures research programs; the toxicologist's view of mix- tures and approaches to their study; and the complementary roles of toxicological, clinical, and epidemiological studies.Studies of tobacco smoke, engine exhaust, combustion products, and air pollutants comprise most of the past research on mixtures.Because of their great experimental control over subjects, exposures, and endpoints, toxicologists tend to consider a wider range of toxic interactions among mixture components and sequential exposures than is practical for human studies.The three fundamental experimental approaches used by toxicologists are integrative (studying the mixture as a whole), dissective (dissecting a mixture to determine causative constituents), and synthetic (studying interactions between agents in simple combinations).Toxicology provides information on potential hazards, mechanisms by which mixture constituents interact to cause effects, and exposure dose-effect relationships; but extrapolation from laboratory data to quantitative human health risks is problematic.Toxicological, clinical, and epidemiological approaches are complementary but are seldom coordinated.Fostering synergistic interactions among the disciplines in studying the risks from mixtures could be advantageous.-
Tumor-Cell Number and Viability as Quality and Efficacy Parameters of Autologous Virus-Modified Cancer Vaccines in Patients With Breast or Ovarian Cancer
Authors: T. Ahlert, W. Sauerbrei, G. Bastert, S. Ruhland, B. Bartik, N. Simiantonaki, J. Schumacher, B. Hacker, M. Schumacher, V. Schirrmacher
Journal: Journal of Clinical Oncology (1997)

The April 1997 article entitled, "Tumor-Cell Number and Viability as Quality and Efficacy Parameters of Autologous Virus-Modified Cancer Vaccines in Patients With Breast or Ovarian Cancer" by Ahlert et al (J Clin Oncol 15:1354–1366, 1997) contained several errors. On page 1354, the affiliation should have read: from the Universität-Frauenklinik Heidelberg; Deutsches Krebsforschungszentrum Heidelberg, Abteilung 710; Forschungspraxis Technologiepark Heidelburg; Institute für medizinische Biometrie und Informatik, Universität Freiburg, Freiburg, Germany. Reference number 36 on page 1365 should have read: 36. Pomer S, Schirrmacher V, Thiele R, et al: Tumor response and 4-year survival data of patients with advanced renal cell carcinoma treated with autologous tumor vaccine and subcutaneous r-IL-2 and IFN-alpha 2b. Int J Oncol 6:941–954, 1995 In addition, Table 5 is reprinted here correctly in its entirety: Please see the PDF for table 5.
Abstract 4389: Post-translational modifications of histone demethylase JMJD1A in prostate cancer cells
Authors: Songhui Xu, Lingling Fan, Xiaolu Cui, Fengbo Zhang, Arif Hussain, Ladan Fazli, Martin Gleave, Jianfei Qi
Journal: Cancer Research (2019)

Abstract Castration-resistant prostate cancer (CRPC) is the major cause of death for prostate cancer (PCa) patients. Re-activation of androgen receptor (AR) activity during androgen-deprivation therapy is believed to underlie CRPC development. We have found that histone demethylase JMJD1A primarily regulates AR and c-Myc activity and thus plays a key role in promoting PCa cell proliferation or survival. Unfortunately, specific JMJD1A inhibitors are not yet available. Here, we identified several post-translational modifications of JMJD1A by performing the JMJD1A immunoprecipitation and mass spectrometry analysis. These modifications include the canonical ubiquitination that targets JMJD1A for proteasome-dependent degradation, non-canonical ubiquitination that enhances the recruitment of co-activators, as well as those that can regulate these ubiquitination events. We also found that these modifications could be manipulated by commercially available inhibitors, to reduce the JMJD1A protein level and prostate cancer cell growth. Thus, targeting the JMJD1A modifications may serve as an alternative means to inhibit JMJD1A activity for the anti-PCa therapy. Note: This abstract was not presented at the meeting. Citation Format: Songhui Xu, Lingling Fan, Xiaolu Cui, Fengbo Zhang, Arif Hussain, Ladan Fazli, Martin Gleave, Jianfei Qi. Post-translational modifications of histone demethylase JMJD1A in prostate cancer cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4389.
Poinsettias
Authors: M. Therese Southgate
Journal: JAMA (1998)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Fatal chlormethiazole poisoning in chronic alcoholics.
Authors: J M Horder
Journal: BMJ (1977)

aspirin, while opiates and their derivatives cause unwanted central nervous depression.Indomethacin seems to provide effective analgesia without making the patient drowsy, and based on this limited experience I strongly recommend it for this purpose.Other similar drugs which combine analgesic and anti- inflammatory properties might prove to be equally effective.
Chemotherapy (Ctx) use and adoption of new agents in older versus younger patients (pts) with metastatic colorectal cancer (mCRC).
Authors: Namrata Vijayvergia, Tianyu Li, Michael J. Hall, Yu-Ning Wong, Steven J. Cohen, Efrat Dotan
Journal: Journal of Clinical Oncology (2016)

e21531 Background: The treatment of mCRC has changed substantially in the last 2 decades however adoption of new drugs is well studied in older pts. We studied the effect of age and comorbidities on the adoption of irinotecan (Iri) and oxaliplatin (Ox) in mCRC pts over a 15 year timespan. Methods: mCRC pts receiving 5-Fluorouracil (5FU) based Ctx (identified by ICD-9 / HCPCS (J) codes) between 1995-2009 were studied using the LifeLink Health Plan Claims Database, and evaluated based on age ( > 70 vs ≤ 70y). The fraction of pts receiving Ctx was calculated at yearly intervals and any other agent received with 5FU defined combination Ctx. Charlson Comorbidity Index (CCI) was used to assess comorbidity burden. Wilcoxon's and χ2test were used in univariate and logistic regression in multivariate analyses (MVA). Results: 16087 pts were identified with a median age of 61y; 36% pts > 70y and 55% males. The difference in proportions of older vs younger pts receiving Ctx for mCRC remained stable over the 15 year period. There was an increase in the fraction of pts with CCI > 1 over time (14% in 1996; 40% after 2004 (p < 0.05). Older pts had higher rate of CCI > 1 (Table). Use of single agent 5FU declined in both groups over time. After FDA approval, use of Iri was lower in older pts (15 vs 38% in 1998, p < 0.05), but this difference resolved by 2002 (62% both groups, p = 0.9). Similarly, Ox was used more frequently in younger pts after initial approval (15 vs 22% in 2003), with decrease in this difference by 2009 (60 vs 64%,p = 0.95).Older pts were less likely to get > 2 agents when compared to younger (15 vs 22%, 29 vs 39% and 11 vs 16% in 2003, 2006 & 2009 respectively, p < 0.001). On MVA, likelihood of receiving combination Ctx increased over time [OR 1.2; p < 0.001], but was lower in older pts [OR 0.65; p < 0.001] and pts with CCI > 1 [OR 0.84; p < 0.001]. Conclusions: In a group of commercially insured pts, fewer older pts received Ctx for mCRC (24% of cohort vs 76% younger pts) and the adoption of new agents into the treatment of older pts lags behind that of younger pts. However, oncologists have become more comfortable treating older pts with comorbidities over time. N > 70 (%) 3881 (24) < 70 (%) 12206 (76) CCI > 1* 51 35 # agent* 1 30 20 2 51 54 3 19 26 *p < 0.05
Incorrect Country.
Journal: JAMA (1990)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 1814: Carboxyl-terminal truncated HBx represses lncRNA-LOC to promote cell metastasis
Authors: Yang Hsiang Lin, Chau-Ting Yeh, Kwang-Huei Lin
Journal: Cancer Research (2019)

Abstract Hepatocellular carcinoma (HCC) is one of the most common and aggressive human malignancy in the world. The poor prognosis of HCC is partly due to a high incidence rate of extrahepatic metastases. Several studies have shown that the relative risk of HCC among hepatitis B virus (HBV) carrier is higher than non-carrier group. Among the four proteins translated by HBV, X-gene (HBx) has been correlated with oncogenesis of HCC. Meanwhile, it is well known that random HBV genome integration can cause truncation of the HBV genome, especially on the HBx gene locus at the C-terminus (designated as Ct-HBx). The discovery of long non-coding RNA (lncRNA) transcripts has dramatically expanded our understanding of cell biology, especially in cancer. However, the underlying molecular mechanisms of lncRNAs that mediate the metastatic cascade and cancer progression remain largely unclear in liver cancer. In this study, lncRNA-LOC is significantly downregulated in HCC and negatively correlated with overall survival in HCC patients. LncRNA-LOC is negatively regulated by Ct-HBx in vitro and in vivo (HCC specimens). Two novel transcripts of LncRNA-LOC in HepG2 and Huh7 cell lines were identified by 5’ and 3’ rapid amplification of cDNA ends assays, respectively. Overexpression of lncRNA-LOC induced marked inhibition of cell migration, invasion and cell proliferation in vitro. On the other hand, these phenotypes were reversed upon knockdown of lncRNA-LOC in cells. Mechanically, levels of p-STAT3 (Tyr705 and Ser727), p-c-Jun (Ser63) and Snail were decreased in lncRNA-LOC-overexpressing cells, compared to control cells. Our data collectively highlight that novel regulatory associations among lncRNA-LOC, Ct-HBx, p-STAT3, p-c-Jun and Snail are an important determinant of metastasis in HCC cells and support the potential utility of lncRNA-LOC as a therapeutic strategy for HCC. Citation Format: Yang Hsiang Lin, Chau-Ting Yeh, Kwang-Huei Lin. Carboxyl-terminal truncated HBx represses lncRNA-LOC to promote cell metastasis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1814.
Injuries of the Face and Jaw and Their Repair, and the Treatment of Fractured Jaws.
Journal: JAMA (1918)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
CAREERS IN PUBLIC HEALTH SERVICE
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Predictors of one-year pretransplant survival in patients with cirrhosis
Authors: M Oellerich
Journal: Hepatology (1991)

The aim of this prospective study was to examine the usefulness of flow-dependent dynamic liver function tests and conventional methods of evaluating liver function as predictors of pretransplant survival in patients with advanced cirrhosis. Patients who underwent orthotopic liver transplantation within the follow-up period of 365 days were excluded. One hundred one patients with histologically confirmed cirrhosis were studied. Fifty-eight patients had post-hepatitic cirrhosis, 13 had cryptogenic cirrhosis and 30 had biliary cirrhosis. During follow-up, 28 patients died of their liver diseases. At entry, we recorded indocyanine green half-life, monoethylglycinexylidide formation from lidocaine, bilirubin and albumin serum concentrations, activities of cholinesterase and alkaline phosphatase, prothrombin time, clinical complications of ascites and encephalopathy and the Pugh score. These variables were subjected as covariates to a stepwise survival analysis by use of the Cox proportional-hazards model. At the final step, Pugh score, monoethylglycinexylidide formation and indocyanine green half-life were found to be the only independent variables significantly related to 1-yr survival. The parallel combination of Pugh score and monoethylglycinexylidide test yielded the highest prognostic sensitivity (82%). The series approach combining either the Pugh score and indocyanine green test or the monoethylglycinexylidide and indocyanine green tests was associated with the highest specificity (96%/97%) and high predictive values of a positive result (81%/82%). These findings suggest that appropriate combinations of the studied flow-dependent dynamic liver function tests and the Pugh score could be useful in improving transplant candidate selection and the timing of transplantation. (HEPATOLOGY 1991;14:1029–1034.)
THE PHARMACOLOGY OF "SOMNOS."
Journal: JAMA (1906)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Dangers of squint.
Journal: BMJ (1967)

long-standing renal disease.J. J. McPhaul and colleagues' described the development of autonomous hyperparathyroidism after restoration of renal function by a transplant.After transplantation there was marked hypophosphataemia, phosphaturia, hypercalciuria, and hypercalcaemia.Patients with this syndrome may require removal of the parathyroid glands to prevent formation of stones and decalcification of the bones.iJ. F. Bravo and colleagues' have reviewed 60 long-term surviving patients with renal transplants, the mean follow-up being 491 days from operation.Of these patients 38% had one or more clinical signs of connective-tissue disorder, apart from muscle weakness, skin diseases, osteoporosis, or neuro- pathy.Five patients suffered from avascular necrosis of the bone, five from synovitis, thirteen from arthralgia, and ten from diffuse musculo-skeletal pain.Anti-gammaglobulin activity against human globulin was found between the second and twenty-eighth weeks after operation in 93 % of cases regardless of the presence or absence of rheumatic disorders.Antibodies to deoxyribonucleic acid and ribonucleic acid were found in 40% and 28% respectively.These workers were unable to detect antibodies to specific constituents in synovial membranes, skeletal muscle, blood vessels, liver, or kidney.Determination of plasma lipids showed fluctuating abnorm- alities in free and esterified cholesterol, phospholipid, tri- -